Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 13/20 | 0.40 |
| ▸ | CDC7 | O00311 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102138 | 0.85 | ROCK1 (0.41) | MAPTROCK1CDC7CDK2ALDH1A1 | |
| SCHEMBL1163857 | 0.84 | ROCK1 (0.40) | MAPTROCK1CDC7CDK2ALDH1A1 | |
| SCHEMBL11938728 | 0.84 | ROCK1 (0.46) | MAPTROCK1CDC7CDK2ALDH1A1 | |
| SCHEMBL5096259 | 0.84 | MAPT (0.44) | MAPTROCK1CDC7CDK2ALDH1A1 | |
| SCHEMBL14837506 | 0.84 | ROCK1 (0.39) | MAPTROCK1CDC7CDK2 | |
| SCHEMBL5096225 | 0.83 | LOXL2 (0.43) | ROCK1 | |
| SCHEMBL3817892 | 0.82 | MAPK8 (0.38) | MAPTROCK1CDC7CDK2ALDH1A1 | |
| SCHEMBL5090451 | 0.82 | ROCK1 (0.38) | MAPTROCK1SMN1; SMN2 | |
| SCHEMBL5096812 | 0.82 | ROCK1 (0.49) | MAPTROCK1CDC7CDK2ALDH1A1 | |
| SCHEMBL14193120 | 0.81 | ROCK1 (0.38) | MAPTROCK1CDC7CDK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | MAPT 966/4885ROCK1 497/4885CDC7 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.